Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy

被引：0

作者：

Zhenfei Li

Mohammad Alyamani

Jianneng Li

Kevin Rogacki

Mohamed Abazeed

Sunil K. Upadhyay

Steven P. Balk

Mary-Ellen Taplin

Richard J. Auchus

Nima Sharifi

机构：

[1] Lerner Research Institute,Department of Cancer Biology

[2] Cleveland Clinic,Department of Radiation Oncology

[3] Taussig Cancer Institute,Departments of Pharmacology and Internal Medicine, Division of Endocrinology and Metabolism

[4] Cleveland Clinic,Department of Urology

[5] University of Michigan Medical School,Department of Hematology and Oncology

[6] Beth Israel Deaconess Medical Center,undefined

[7] Harvard Medical School,undefined

[8] Dana-Farber Cancer Institute,undefined

[9] Harvard Medical School,undefined

[10] Glickman Urological and Kidney Institute,undefined

[11] Cleveland Clinic,undefined

[12] Taussig Cancer Institute,undefined

[13] Cleveland Clinic,undefined

来源：

Nature | 2016年 / 533卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The prostate cancer drug abiraterone can be metabolized into several substances with different effects, and optimization of this process could be helpful for fine-tuning the treatment of prostate cancer.

引用

页码：547 / 551

页数：4

共 50 条

[31] Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Florian Handle
Stefan Prekovic
Christine Helsen
Thomas Van den Broeck
Elien Smeets
Lisa Moris
Roy Eerlings
Sarah El Kharraz
Alfonso Urbanucci
Ian G. Mills
Steven Joniau
Gerhardt Attard
Frank Claessens
Scientific Reports, 9
[32] Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Handle, Florian
Prekovic, Stefan
Helsen, Christine
Van den Broeck, Thomas
Smeets, Elien
Moris, Lisa
Eerlings, Roy
El Kharraz, Sarah
Urbanucci, Alfonso
Mills, Ian G.
Joniau, Steven
Attard, Gerhardt
Claessens, Frank
SCIENTIFIC REPORTS, 2019, 9 (1)
[33] Macrophages promote anti-androgen resistance in prostate cancer bone disease
Li, Xue-Feng
Selli, Cigdem
Zhou, Han-Lin
Cao, Jian
Wu, Shuiqing
Ma, Ruo-Yu
Lu, Ye
Zhang, Cheng-Bin
Xun, Bijie
Lam, Alyson D.
Pang, Xiao-Cong
Fernando, Anu
Zhang, Zeda
Unciti-Broceta, Asier
Carragher, Neil O.
Ramachandran, Prakash
Henderson, Neil C.
Sun, Ling-Ling
Hu, Hai-Yan
Li, Gui-Bo
Sawyers, Charles
Qian, Bin-Zhi
JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 220 (04):
[34] Anti-androgen therapy in triple-negative breast cancer
Barton, Valerie N.
Gordon, Michael A.
Richer, Jennifer K.
Elias, Anthony
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (04) : 305 - 308
[35] Medical groups, researchers fine-tune clopidogrel therapy
Thompson, Cheryl A.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (24) : 2318 - +
[36] Macrophage promotion of anti-androgen resistance in prostate cancer bone disease
Li, Xue-Feng
Selli, Cigdem
Unciti-Broceta, Asier
Carragher, Neil O.
Hu, Hai-Yan
Sawyers, Charles L.
Qian, Bin-Zhi
CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)
[37] EFFECT OF FLUTAMIDE, AN ANTI-ANDROGEN, ON STAGE-D CANCER OF THE PROSTATE
KASSEM, NY
NERI, RO
MUNROE, JS
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (02) : 256 - 256
[38] Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer?
Roach, M
Reese, D
Weinberg, V
Small, EJ
Carroll, PR
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 448 - 449
[39] Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Huang, Jian
Lin, Biyun
Li, Benyi
FRONTIERS IN ONCOLOGY, 2022, 12
[40] Anti-androgen activity of natural product "bizzy" in prostate cancer cells
Debose, Lakesha
Fontenot, Krystal
Koppula, Sowmya
Solipuram, Rajasree
Hurst, Angela
Gray, Wesley
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 874 - 874

← 1 2 3 4 5 →